Azithromycin, a novel azalide antibiotic, concentrated in human and mouse polymorphonuclear leukocytes (PMNs), murine peritoneal macrophages, and mouse and rat alveolar macrophages, attaining intracellular concentrations up to 226 times the external concentration in vitro. In murine peritoneal macrophages, azithromycin achieved concentration gradients (internal to external) up to 26 times higher than erythromycin. The cellular uptake of azithromycin was dependent on temperature, viability, and pH and was decreased by 2,4-dinitrophenol. Azithromycin did not decrease phagocyte-mediated bactericidal activity or affect PMN or macrophage oxidative burst activity (H202 release or Nitro Blue Tetrazolium reduction, respectively). Azithromycin remained in cells for several hours, even after extracellular drug was removed. However, its release was significantly enhanced by phagocytosis of Staphylococcus aureus (82 versus 23% by 1.5 h). In vivo, 0.05 ,ig of azithromycin was found in peritoneal fluids of mice 20 h after oral treatment with a dose of 50 mg/kg. Following caseinate-induced PMN infiltration, there was a sixfold increase in peritoneal cavity azithromycin to 0.32 ,ug, most of which was intracellular. Therefore, the uptake, transport, and later release of azithromycin by these cells demonstrate that phagocytes may deliver active drug to sites of infection.
The ability of an antimicrobial agent to penetrate into phagocytic cells is essential for activity against facultative intracellular organisms (11). However, the potential benefits attained from achieving high intraphagocytic concentrations are uncertain since intracellular bactericidal activity may not be proportionally enhanced (18) . In fact, in some instances, a decrease in potential phagocyte-mediated bacterial killing mechanisms (02 and H202) have been reported (13) . On the other hand, one potential advantage of intracellular concentration with important implications for in vivo antibacterial efficacy is the targeted delivery of active drug to infection sites by the phagocyte. This was illustrated by Deysine et al. (4) , who loaded leukocytes in vitro with polyacrylamide beads containing kanamycin and found that these cells, when injected in vivo, could carry the antibiotic to sites of infection. Even though in vitro loading of phagocytes is clinically impractical, this observation suggests that antibiotics with the ability to concentrate and be retained by cells in vivo could act in concert with the host immune system and be delivered to specific sites as part of the normal host cellular response to infection. Since efflux of antibiotics from cells has been demonstrated in vitro (2, 7) , release of an antibiotic from phagocytes at these sites could produce locally high concentrations of active drug. Therefore, the ability of an antimicrobial agent to concentrate in phagocytes may be important for activity against extracellular, as well as intracellular, bacteria at localized areas of infection.
Azithromycin 993 ; also designated XZ-450 [Pliva Pharmaceutical, Zagreb, Yugoslavia]) is a novel azalide antibiotic with improved in vivo potency, compared with that of erythromycin, against localized soft tissue infections (5) . It differs from erythromycin in that it has a 15-membered ring (not 14) and contains two, rather than one, basic amine groups (1) . This modification results in significant changes in pharmacokinetics (i.e., greater tissue penetration and longer * Corresponding author. elimination half-life) (5) and spectrum (i.e., potency against gram-negative bacteria) (16) . Azithromycin has also been reported to have activity against intracellular pathogens (16, 20) . Therefore, we examined the ability of azithromycin to enter and concentrate in phagocytic cells. In addition, the ability of phagocytes to retain, deliver, and potentially release azithromycin at infection sites was examined. The effect of azithromycin on normal phagocytic bactericidal mechanisms was also assessed.
MATERIALS AND METHODS Animals. C3H/HeN male mice (15 to 18 g) and inbred Fisher 344 male rats (200 to 225 g) were purchased from Charles River Breeding Laboratories, Inc., Raleigh, N.C., and Kingston, N.Y., respectively.
Antibiotics. Radiolabeled azithromycin (9-deoxo-9a-aza9a-[14C]methyl-9a-homoerythromycin A) was prepared by methylation at the 9a-aza site of the precursor 9-deoxo9a-aza-9a-homoerythromycin A by a modified Clarke-Eschweiler procedure, using radiolabeled aqueous formaldehyde (Dupont, NEN Research Products, Boston, Mass. (12) , murine and rat alveolar macrophages (9) , and murine resident peritoneal macrophages (6 Determination of oxidative burst activity. The oxidative burst activity of murine PMNs was determined by measuring H202 production (14) . Cells were exposed -to various concentrations of azithromycin for 2 h, washed, and suspended in phenol red-horseradish peroxidase medium which contained additional azithromycin equivalent to the initial concentration. The cells were warmed to 37°C for 30 min. PMA was then added to stimulate an oxidative burst.
Macrophage oxidative activity was determined by NBT reduction (17 (Fig. 2) . In contrast, the concentration gradient (I/E ratio) was constant for the concentrations evaluated (1 to 100 ,ug/ml).
Further experiments were done in an attempt to determine the mechanism(s) of azithromycin uptake by peritoneal macrophages. Uptake of azithromycin by phagocytes was prevented when cells were incubated at 4°C or after pretreatment of cells with formaldehyde (10% in phosphate buffer). Preincubating macrophages for 30 min in 1.0 mM DNP reduced the intracellular concentration of azithromycin by 32%. No effect on uptake was observed with 100 ,uM DNP. Uptake of azithromycin was not dependent upon the presence of serum over a range of 0 to 40%. Uptake was prevented, however, when cells were incubated at an acid pH (6.0) but was not significantly altered by incubation at an alkaline pH (8.4) .
Since the uptake of some antibiotics has been reported to be mediated by membrane carrier systems (7, 8) , the effects of membrane stimulants were also examined. Preincubation of macrophages with S. aureus (opsonized with fresh mouse serum for 1 h at 37°C) at a ratio of 1:40 reduced, but did not prevent, uptake of azithromycin (Table 2 ). In contrast, preexposure to PMA had no effect.
Release of azithromycin from macrophages. Azithromycin was released slowly from macrophages after the removal of extracellular drug. After 1 h, only 19% of the azithromycin was released into the extracellular medium (Fig. 3) . The release of azithromycin continued for 24 h. At this time, 93.3% was released. Thus, 6.7% of the initial amount remained cell associated (I/E ratio at this time was 85). In contrast, 1 h after the removal of extracellular antibiotic, 85% of the erythromycin had egressed from the cells, and by 3 h essentially all of the erythromycin had been released. In view of the relatively long half-life of azithromycin in cells, the effects of membrane stimulants on release were determined. Phagocytosis of opsonized S. aureus (40 cells per macrophage) significantly enhanced the release of azithromycin (Fig. 4) . In contrast, PMA neither enhanced nor diminished release.
PMN and macrophage oxidative burst activity. Even though PMNs and macrophages concentrated azithromycin, no suppression of H202 release or NBT reduction was observed when cells were exposed to 50 ,ug of azithromycin per ml and then stimulated with PMA (Table 3) . Similar results were observed when cells were exposed to concentrations of azithromycin as low as 0.05 ,ug/ml or when ing macrophages not loaded with azithromycin had increases in bacterial numbers (CFU) from 6 x 105/ml at 1 h to 2 x 108/ml at 6 h and 37 x 109/ml at 24 h. In contrast, wells containing macrophages preexposed to azithromycin (free azithromycin was washed out prior to the addition of bacteria) had no increase in bacterial numbers at 6 h, and in fact, bacterial numbers decreased after 24 h, resulting in <102 CFU/ml. If all the intracellular azithromycin had been released from the macrophages, the concentration of azithromycin in the extracellular fluid should have been approximately 1.09 pLg/ml, a value above the MIC but below the MBC.
In vivo uptake and delivery of azithromycin by phagocytic cells. The delivery of azithromycin to the peritoneal cavity was examined in peritoneal lavage fluid after oral treatment of mice with 50 mg of [14C]azithromycin per kg. Initially, the azithromycin concentration in the peritoneal cavity increased in caseinate-treated animals in direct proportion to the number of PMNs migrating into this site (Table 4) . By 20 h after caseinate injection, the total azithromycin in the peritoneal cavity increased sixfold (75% cell associated; intracellular concentration, 79 jig/ml). This increase in azithromycin did not appear to be a result of perturbation of the blood-peritoneum boundary since (i) essentially no erythrocytes were observed in the lavage fluid, (ii) most of the azithromycin was found in the leukocyte pellet (and not free within the fluid), and (iii) azithromycin increased over time as more PMNs migrated into this site.
Delivery of azithromycin to the peritoneal cavity by monocytes was also examined. Animals were treated twice 785, 1988) .
Exposure of phagocytes to S. aureus enhanced the release of azithromycin from cells (Fig. 4) and reduced its in vitro concentrating ability. Reduced uptake during in vitro phagocytosis has also been reported for roxithromycin and erythromycin (7), whereas the opposite has been reported for clindamycin (18) . The uptake of antibiotics by phagocytes is important. However, it would not be beneficial if all the antibiotic entered the phagocyte in the presence of extracellular bacteria (e.g., at infection sites). Also, even though azithromycin uptake was decreased by S. aureus, it was not prevented. The cause for this decreased uptake of azithromycin in the presence of bacteria might relate to the enhanced release shown to occur following phagocytosis, thus altering the equilibrium in favor of decreased uptake.
The relative contribution of active versus passive transport in the uptake of antibiotics is difficult to determine. It is conceivable that both processes could be involved in the uptake of azithromycin. The metabolic inhibitior DNP inhibited azithromycin uptake, suggesting active transport is involved. However, only a high concentration (1 mM) was effective, and even then only 32% inhibition was observed compared with controls. Passive transport processes are also suggested by the direct relationship observed between extracellular concentration and intracellular accumulation and by the inhibition of uptake by low temperature or fixation, either of which could decrease membrane fluidity and thus prevent diffusion. Although the extent of uptake was greater than usual for a passive transport process, one mechanism by which diffusion may lead to intracellular accumulation might relate to the tendency of basic compounds to be lysosomotropic and to become trapped in lysosomes as a result of the acidic pH (3, 15) . The presence of two basic amine groups in the structure of azithromycin (1) may allow for greater ionization and trapping than that which may occur with classical macrolides, like erythromycin, which contain only one basic amine group. Along these lines, acidity did inhibit diffusion of azithromycin into cells. The partial inhibition of uptake by DNP might therefore be explained by inhibition of proton pump activity, which is required to maintain lysosomal pH (3), thus leading to more extensive uptake and trapping.
In summary, azithromycin was shown in vitro and in vivo to concentrate in phagocytic cells. The presence of increased levels of azithromycin in the peritoneal cavities of stimulated mice suggests the potential for phagocytes to deliver azithromycin to sites of infection. This, coupled with the enhanced release of azithromycin from macrophages in the presence of bacteria, further suggests that azithromycin, in concert with the host immune system, is a directed, perhaps sustainedrelease, antimicrobial agent at infection sites.
